Fulgent Genetics Inc (NAS:FLGT)
$ 22.5 0 (0%) Market Cap: 673.30 Mil Enterprise Value: 382.09 Mil PE Ratio: 0 PB Ratio: 0.60 GF Score: 74/100

Fulgent Genetics Inc at Credit Suisse Healthcare Conference Transcript

Nov 08, 2022 / 04:00PM GMT
Release Date Price: $34.7 (-2.31%)
Daniel Louis Leonard;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Great. Well, welcome, everybody, to the Credit Suisse Healthcare Conference. I'm Dan Leonard, the life sciences and diagnostics analyst at Credit Suisse. We're happy to kick off the event with Fulgent Genetics. Representing Fulgent, we have Ming Hsieh, CEO; Paul Kim, CFO; Brandon Perthuis, Chief Commercial Officer; Dr. Larry Weiss, Chief Medical Officer; and Dr. Ray Yin, Chief Scientific Officer of Fulgent Pharma. Thank you, everybody, for coming.

Questions & Answers

Daniel Louis Leonard;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Ming, I wanted to start off the session since you reported your third quarter results last night, asking if you could give us any key takeaways, highlights from that report.

Ming Hsieh
Fulgent Genetics, Inc. - Chairman & CEO

Okay. Thank you, Dan. And thank you, everyone, who joined our presentation today. .

So I think

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot